{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T08:28:17Z","timestamp":1786523297760,"version":"build-2736575974"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"\n Introduction<\/jats:title>\n Respiratory disease significantly impacts quality of life at the same time economic burden. Mucolytic agents are widely used in respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, and upper respiratory tract infections (URTIs). However, real-world differences in clinical outcomes between prescription-guided and over-the-counter (OTC) mucolytic use in community settings remain inadequately characterized.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n The present study aimed to compare symptom improvement and adverse effects between prescription based and OTC mucolytic users, and to evaluate patterns of usage and healthcare seeking behaviour consultation in a community setting.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n A longitudinal observational study conducted among 200 participants categorized into OTC and prescription groups conducted after getting institutional Ethical approval (BVDUMC\/IEC\/399\/25-26). Data collected using structured questionnaires assessing symptom scores, adverse effects, and healthcare utilization. Statistical analysis included descriptive statistics and Chi-square test. A p value of &lt;0.05 was considered statistically significant. Ethical approval was obtained before starting the study.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The prescription group demonstrated a statistically significant improvement in symptoms, with mean COPD Assessment Test (CAT) scores decreasing from 21 to 18 (p &lt; 0.01). In contrast, the OTC group exhibited a significant worsening of symptoms, with mean scores increasing from 26.5 to 30 (\n p<\/jats:italic>\n &lt; 0.01). Prescription-based therapy was associated with better symptom control, appropriate drug selection, and adherence to recommended dosing regimens. Conversely, OTC use was characterized by inconsistent dosing, inappropriate drug selection, and suboptimal therapeutic outcomes. The incidence of adverse drug reactions was slightly higher in the Prescription group, predominantly gastrointestinal in nature. Furthermore, awareness regarding appropriate indications, dosage, and duration of mucolytic therapy was significantly lower among OTC users.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Prescription mucolytic therapy demonstrated better outcomes compared to OTC use, likely due to structured treatment and medical supervision. These findings indicate the importance of rational prescribing and patient education in respiratory disease management.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fphar.2026.1901723","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T07:41:03Z","timestamp":1786520463000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A comparative study of the impact of prescription and non-prescription mucolytic agents on respiratory disease management in a community-based population"],"prefix":"10.3389","volume":"17","author":[{"given":"Jayshree Shriram","family":"Dawane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaushal Navanath","family":"Mehetre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juee","family":"Shinde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1164\/rccm.202301-0106pp","article-title":"Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary","volume":"207","author":"Agust\u00ed","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B3","first-page":"45","article-title":"Carbocisteine: mechanism of action and clinical efficacy","volume":"55","author":"Braga","year":"1989","journal-title":"Respiration"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/17534666241279115","article-title":"Long-acting muscarinic antagonist and long-acting \u03b22-agonist combination for maintenance therapy-na\u00efve patients with COPD: a narrative review","volume":"18","author":"Buhl","year":"2024","journal-title":"Ther. Adv. Respir. Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.pupt.2017.11.009","article-title":"Influence of mucolytic therapy on chronic bronchitis and COPD","volume":"23","author":"Cazzola","year":"2010","journal-title":"Pulm. Pharmacol. Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/s0929-693x(02)00091-x","article-title":"Mucolytic agents for acute respiratory tract infections in infants: safety concerns","volume":"25","author":"Chalumeau","year":"2002","journal-title":"Drug Saf."},{"key":"B7","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2147\/COPD.S343108","article-title":"The importance of self-management in the context of personalized care in COPD","volume":"17","author":"Cravo","year":"2022","journal-title":"Int. J. Chron. Obstruct Pulmon Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1378\/chest.124.6.2178","article-title":"Effect of guaifenesin on cough reflex sensitivity","volume":"124","author":"Dicpinigaitis","year":"2003","journal-title":"Chest"},{"key":"B11","volume-title":"Guideline on Good Pharmacovigilance Practices (GVP)","year":"2024"},{"key":"B12","first-page":"12","article-title":"Use of over-the-counter medications in older adults","volume":"36","author":"George","year":"2006","journal-title":"J. Pharm. Pract. Res."},{"key":"B13","volume-title":"Global Strategy for Prevention, Diagnosis and Management of COPD: 2023 Report","year":"2023"},{"key":"B14","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2025 report","year":"2025","journal-title":"Font. WI GOLD"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1056\/nejmoa0909883","article-title":"Susceptibility to exacerbation in chronic obstructive pulmonary disease","volume":"363","author":"Hurst","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B16","volume-title":"Community Pharmacy at the Forefront of Self-Care","year":"2023"},{"key":"B8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.4103\/ijhas.IJHAS_120_19","article-title":"Knowledge and practice of community pharmacists toward dispensing of cough medications for children Khartoum State: A cross-sectional study","volume":"9","author":"Ibrahim","year":"2020","journal-title":"Intern J Health Allied Sci."},{"key":"B2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1186\/s12913-026-14114-z","article-title":"Self-medication among older adults in rural India: structural gaps in primary care and pain management","volume":"26","author":"Kanougiya","year":"2026","journal-title":"BMC Health Services Research"},{"key":"B17","first-page":"106684","article-title":"Treatment of acute cough in adults and children with ambroxol: a review","volume":"190","author":"Kardos","year":"2021","journal-title":"Respir. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1124\/pr.119.018150","article-title":"Pharmacology and therapeutics of bronchodilators revisited","volume":"72","author":"Matera","year":"2020","journal-title":"Pharmacol. Rev."},{"key":"B19","volume-title":"Medical Dictionary for Regulatory Activities (Meddra), Version 27.0","year":"2024"},{"key":"B20","doi-asserted-by":"publisher","first-page":"6522","DOI":"10.3390\/jcm11226623","article-title":"LABA\/LAMA as first-line therapy for chronic obstructive pulmonary disease: a summary of the evidence and guideline recommendations","volume":"11","author":"Miravitlles","year":"2022","journal-title":"J. Clin. Med."},{"key":"B21","volume-title":"Chronic Obstructive Pulmonary Disease in over 16s: Diagnosis and Management","year":"2018"},{"key":"B22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.15326\/jcopdf.6.4.2019.0139","article-title":"The role of guaifenesin in respiratory disease management","volume":"14","author":"Ohar","year":"2019","journal-title":"Multidiscip. Respir. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1136\/bmj.322.7297.1271","article-title":"Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review","volume":"322","author":"Poole","year":"2001","journal-title":"BMJ"},{"key":"B24","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/copd.s3036","article-title":"Medication adherence issues in patients treated for COPD","volume":"3","author":"Restrepo","year":"2008","journal-title":"Int. J. Chron. Obstruct Pulmon Dis."},{"key":"B25","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.4187\/respcare.07521134","article-title":"Airway mucus hypersecretion in chronic inflammatory airway diseases","volume":"52","author":"Rogers","year":"2007","journal-title":"Respir. Care"},{"key":"B26","doi-asserted-by":"crossref","first-page":"859","DOI":"10.4187\/respcare.07520859","article-title":"Mucolytics, expectorants, and mucokinetic medications","volume":"52","author":"Rubin","year":"2007","journal-title":"Respir. Care"},{"key":"B27","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.pharmthera.2013.09.006","article-title":"Existing and potential therapeutic uses for N-acetylcysteine","volume":"141","author":"Rushworth","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1186\/1465-9921-13-98","article-title":"Mechanisms of action of guaifenesin","volume":"106","author":"Seagrave","year":"2012","journal-title":"Respir. Med."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-XXXX-X","article-title":"Chronic obstructive pulmonary disease (COPD): developments in pharmacological treatments","author":"Singh","year":"2025","journal-title":"Drugs"},{"key":"B30","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1034\/j.1399-3003.2000.16b12.x","article-title":"The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review","volume":"16","author":"Stey","year":"2000","journal-title":"Eur. Respir. J."},{"key":"B34","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1186\/s12889-025-23113-4","article-title":"Status and influencing factors of OTC medicine use for self-medication in cold and cough: a cross-sectional survey in Japan","volume":"25","author":"Tian","year":"2025","journal-title":"BMC Public Health"},{"key":"B31","volume-title":"The Role of the Pharmacist in self-care and self-medication","year":"1998"},{"key":"B32","volume-title":"Guidelines for the Regulatory Assessment of Medicinal Products for Use in self-medication","year":"2000"},{"key":"B33","volume-title":"WHO Guideline on Self-Care Interventions for Health and well-being","year":"2022"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/S0140-6736(08)60869-7","article-title":"Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE study): a randomised placebo-controlled study","volume":"371","author":"Zheng","year":"2008","journal-title":"Lancet"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1901723\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T07:41:05Z","timestamp":1786520465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1901723\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":34,"alternative-id":["10.3389\/fphar.2026.1901723"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1901723","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"article-number":"1901723"}}